Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial
Charles Flexner, Camlin Tierney, Robert Gross, Adriana Andrade, Christina Lalama, Susan H Eshleman, Judith Aberg, Ian Sanne, Teresa Parsons, Angela Kashuba, Susan L Rosenkranz, Anne Kmack, Elaine Ferguson, Marjorie Dehlinger, Donna Mildvan, ACTG A5073 Study Team, Jorge L Santana Bagur, Olga Mendez, Margie Vasquez, Karen Cavanagh, Kathleen Squires, Bartolo Santos, Andrea Weiss, Robin McKenzie, Carl J Fichtenbaum, Fran Hyc, Martha Greenwald, Mitchell Goldman, Karen Tashima, Pamela Poethke, Cathi Basler, Monica Carten, Cindy Firnhaber, Ian Sanne, Aleshia Thomas, David Perlman, Gwen Costantini, Sondra Middleton, Ann Conrad, Kim Whitely, Susan L Koletar, Mark D Hite, Joseph Eron, David Currin, Richard Pollard, Nancy Fitch, Brenda Jackson, Rebecca Basham, Christine Hurley, Mary Adams, Ann C Collier, Beck A Royer, Kim Epperson, Tim Lane, David Currin, Sue Richard, Henry H Balfour Jr, Christine Fietzer, Hector Bolivar, Margaret A Fischl, Richard Pollard, Abby Olusanya, Robert Redfield, Charles Davis, Jack Degnan, Dee Dee Pacheco, Karen Tashima, Joan Gormley, Sharon Riddler, Carol Oriss, Lorna Nagamine, Scott Souza, Nayef El-Daher, Carol Greisberger, John Black, Beth Zwickl, Timothy Flanigan, Joan Gormley, Andrea Weiss, Robin McKenzie, Charles Flexner, Camlin Tierney, Robert Gross, Adriana Andrade, Christina Lalama, Susan H Eshleman, Judith Aberg, Ian Sanne, Teresa Parsons, Angela Kashuba, Susan L Rosenkranz, Anne Kmack, Elaine Ferguson, Marjorie Dehlinger, Donna Mildvan, ACTG A5073 Study Team, Jorge L Santana Bagur, Olga Mendez, Margie Vasquez, Karen Cavanagh, Kathleen Squires, Bartolo Santos, Andrea Weiss, Robin McKenzie, Carl J Fichtenbaum, Fran Hyc, Martha Greenwald, Mitchell Goldman, Karen Tashima, Pamela Poethke, Cathi Basler, Monica Carten, Cindy Firnhaber, Ian Sanne, Aleshia Thomas, David Perlman, Gwen Costantini, Sondra Middleton, Ann Conrad, Kim Whitely, Susan L Koletar, Mark D Hite, Joseph Eron, David Currin, Richard Pollard, Nancy Fitch, Brenda Jackson, Rebecca Basham, Christine Hurley, Mary Adams, Ann C Collier, Beck A Royer, Kim Epperson, Tim Lane, David Currin, Sue Richard, Henry H Balfour Jr, Christine Fietzer, Hector Bolivar, Margaret A Fischl, Richard Pollard, Abby Olusanya, Robert Redfield, Charles Davis, Jack Degnan, Dee Dee Pacheco, Karen Tashima, Joan Gormley, Sharon Riddler, Carol Oriss, Lorna Nagamine, Scott Souza, Nayef El-Daher, Carol Greisberger, John Black, Beth Zwickl, Timothy Flanigan, Joan Gormley, Andrea Weiss, Robin McKenzie
Abstract
Background: Dosing frequency is an important determinant of regimen effectiveness. Methods. To compare efficacy of once-daily (QD) versus twice-daily (BID) antiretroviral therapy, we randomized human immunodeficiency virus (HIV)-positive, treatment-naive patients to lopinavir-ritonavir (LPV/r) administered at a dosage of 400 mg of lopinavir and 100 mg of ritonavir BID (n = 160) or 800 mg of lopinavir and 200 mg of ritonavir QD (n = 161), plus either emtricitabine 200 mg QD and extended-release stavudine at a dosage of 100 mg QD or tenofovir at a dosage of 300 mg QD. Randomization was stratified by screening HIV RNA level <100,000 copies/mL versus > or = 100,000 copies/mL. The primary efficacy end point was sustained virologic response (SVR; defined as reaching and maintaining an HIV RNA level <200 copies/mL) through week 48.
Results: Subjects were 78% male, 33% Hispanic, and 34% black. A total of 82% of subjects completed the study, and 71% continued to receive the initially assigned dosage schedule. The probability of SVR did not differ significantly for the BID versus QD comparison, with an absolute proportional difference of 0.03 (95% confidence interval [CI], -0.07 to 0.12). The comparison depended on the screening RNA stratum (P=.038); in the higher RNA stratum, the probability of SVR was significantly better in the BID arm than in the QD arm: 0.89 (95% CI, 0.79-0.94) versus 0.76 (95% CI, 0.64-0.84), a difference of 0.13 (95% CI, 0.01-0.25). Lopinavir trough plasma concentrations were higher with BID dosing. Adherence to prescribed doses of LPV/r was 90.6% in the QD arm versus 79.9% in the BID arm (P<.001). Conclusions. Although subjects assigned to QD regimens had better adherence, overall treatment outcomes were similar in the QD and BID arms. Subjects with HIV RNA levels > or =100,000 copies/mL had better SVR with BID regimens at 48 weeks, which suggests a possible advantage in this setting for more frequent dosing. Clinical trial registration. ClinicalTrials.gov registration number: NCT00036452.
Figures
Source: PubMed